Codex DNA

About:

Codex DNA is a synthetic biology company that offers biotechnology research services.

Website: https://codexdna.com

Twitter/X: codex_dna

Top Investors: Northpond Ventures, Oxford Finance LLC, BroadOak Capital Partners

Description:

Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

Total Funding Amount:

$25M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2011-01-01

Contact Email:

hello(AT)codexdna.com

Founders:

Dan Gibson, Todd Nelson

Number of Employees:

101-250

Last Funding Date:

2019-12-19

IPO Status:

Public

Industries:

© 2025 bioDAO.ai